Epilepsy is a common, complex, and chronic neurologic disorder affecting an estimated 0.5-1% of the global population or approximately 50 million people worldwide, 1,2 1.1-2.3 million of whom reside in the US. 3 The ultimate goal of the treatment of epilepsy is to eliminate seizures without producing any side effects. Despite the plethora of antiepileptic drugs (AEDs) that have emerged over the past two decades, between 30 and 50% of patients continue to experience recurrent seizures. Figure 1 summarizes the potential targets for AED pharmacologic actions. 
this group are not well-defined, prognostic factors that may cause intractability include multiple seizure types, complex febrile seizures, and symptomatic or cryptogenic epilepsy. 9 A prospective study by Kwan and Brodie 10 investigated the response to AEDs in 525 patients (nine to 93 years of age) with newly diagnosed epilepsy to identify factors associated with subsequent poor control of seizures. Patients were considered to be seizure-free if they had not experienced a seizure for ≥1 year. The outcomes of patients who received AED therapy are summarized in Figure 2 . Although the overall rate of seizure remission was 63%, the study showed that patients with known or probable structural cerebral abnormality were 1.5 times more likely to have refractory disease than patients with idiopathic epilepsy. The authors also concluded that patients suffering multiple seizures or who were unsuccessfully treated with the initial AED were more likely to suffer from refractory epilepsy. 10 Although the traditional argument against add-on therapy has been that there is a greater likelihood of toxicity with little improvement in outcome, adverse events due to pharmacokinetic and pharmacodynamic interactions between AEDs may be equally likely during the substitution phase. 11, 12 This has been demonstrated in a prospective study of patients in whom treatment with the first AED was unsuccessful, although the results did not reach statistical significance. 13 In this study of patients with inadequate seizure control on the first well-tolerated AED, similar seizure-free rates were observed in those who received substitution monotherapy (n=35, 17%) and those who received combination therapy with a second add-on AED (n=42, 26%). Furthermore, similar incidences of intolerable side effects between the two treatment groups were observed (substitution versus add-on: 26 versus 12%. 13 The definition of intractable or refractory epilepsy has been hotly debated. 14 Recently, the International League Against Epilepsy (ILAE)
proposed a consensus definition of drug-resistant epilepsy and the task force settled on the preferred term 'drug-resistant' to replace the terms medically intractable, refractory, and pharmacoresistant. 15 The consensus for this choice is that drug-resistant is more consistent with the intent of the definition, namely to identify patients for whom there is sufficient information to predict that they will have a substantially poorer prognosis for seizure remission with AEDs compared with the population as a whole. The terms 'intractable' and 'refractory' imply that there is no chance at all of remission, which is never the case. 15 The development of the consensus definition was driven by the growing need among medical practitioners and clinical researchers to adopt a common language in recognizing drug-resistant epilepsy, thereby facilitating comparison and meaningful generation of results across studies in the face of rapidly expanding therapeutic options. 16 Furthermore, the definition could be valuable to patients and their carers, basic scientists, government regulators, legislators, healthcare administrators, insurers, educators, and employers.
However, the proposed definition is not intended to be prescriptive but represents a working framework. 16 The overall framework of definition comprises two levels. Level 1 provides a general scheme to categorize outcome to each therapeutic intervention (both pharmacologic and non-pharmacologic) that includes a minimum data set regarding the intervention that would be needed for such a purpose. Level 1 forms the basis for level 2. Level 2 provides a core definition of drugresistant epilepsy based on the number of informative trials of AEDs that resulted in a treatment failure outcome. It is then possible to adapt, where appropriate, the core definition to specific purposes or clinical scenarios.
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Polytherapy-Rational or Irrational?
Irrational Polytherapy
Although polytherapy is implemented necessarily frequently to treat epilepsy, irrational polytherapy occurs too often. The use of multiple medications may cause adverse effects, drug-drug interactions, patient non-compliance, and medication errors. There is also the added complication of patients taking over-the-counter medications that physicians are not aware of. 17 Furthermore, polytherapy has been associated with an increased incidence of mortality. 18 There are several reasons irrational polytherapy occurs in the treatment of epilepsy. Poor initial diagnosis is a common reason for irrational polytherapy, with patients being prescribed an inappropriate AED in the first place.
Subsequently, if a patient is not improving with the AED already prescribed, a physician may simply add further AEDs to their treatment without reassessing the drug that has already been prescribed.
Cross-titration occurs when a second drug is added. The physician may alter the dosage of drug if an immediate improvement is not achieved or, if an improvement is observed, the patient may inappropriately continue to be administered both drugs as the physician assumes that the combination is responsible for the improvement. In fact, many medication changes may not require cross-titration. carbamazepine, 38% phenytoin). The response rate was higher in patients with idiopathic tonic-clonic seizures compared with patients with partial seizures (61 versus 43%; p<0.01). Furthermore, the response rate in patients with partial and idiopathic tonic-clonic seizures was higher for the valproic acid group than for those treated with phenytoin or carbamazepine. This difference was significant in patients with partial seizures (p=0.014) and when all seizures were included the difference between groups was statistically significant (p=0.001). In this study, synergism between lamotrigine and valproic acid was also shown.
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Moreover, this study lends credence to combination therapy.
Rational choice of drug combinations is currently based more on avoidance of pharmacodynamic or pharmacokinetic side effects than evidence for supra-additive efficacy. Although indications suggest that combinations of AEDs with differing mechanisms of action are most effective, further investigation is necessary, with attention to the effects of the various combinations on both toxicity and seizure control.
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Animal Models and Isobolograms
AED therapy is primarily aimed at reducing excitability through blockage of voltage-gated Na + or Ca + channels, or by increasing inhibition through the enhancement of γ-aminobutyric acid (GABA) currents. 20 In the past AEDs were discovered by serendipity, but the most recent
AEDs have been specifically designed to target one of the many receptors or neurotransmitters involved in the generation of seizures.
Once identified, putative AEDs are first studied in animal models of seizures (usually in rodents) to determine whether they will be effective in generalized or partial seizures, prior to clinical studies. 20, 21 Antiseizure drug screening has not only enabled a large number of relatively safe and effective AEDs onto the market, but it has also allowed further insight into the pathophysiology of seizures. However, it should be understood that this screening of AEDs is carried out in models of seizure and not models of epilepsy. This demonstrates that the 
The Limitations of Polytherapy
The potential for unfavorable drug-drug interactions is a common concern, particularly the effect of older AEDs on the hepatic cytochrome P450 (CYP) enzyme superfamily. 39 Historically, the strongest argument against polytherapy has been the possibility of additive adverse events. 40, 41 However, it has also been argued that the efficacy and toxicity of polytherapy with AEDs is more dependent on total drug load rather than the number of drugs. 42 Drug load is measured as the ratio of prescribed daily dose to the defined daily dose. 43 In one observational study, 44 In order to reduce the potential drug load, it is possible to lower the dose of the initial drug, particularly if the patient in question suffers from or develops adverse effects. However, in the event that all types of AED therapy (monotherapy and polytherapy) fail to fully control seizures, evaluation for surgery should be considered at an early stage, particularly if a structural abnormality such as mesial temporal sclerosis has been identified. 40, 59 It is crucial to assess the likelihood of pseudo-failure or pseudoresistance before the implementation of combination therapy as the majority of patients will respond to monotherapy. Such a situation may transpire if a patient is misdiagnosed, inappropriately treated with AED for a particular type or syndrome of seizure and epilepsy, the dose administered is not high enough, adherence to treatment is poor, or inappropriate lifestyle factors such as alcohol or recreational drug abuse are identified. 40 The existing monotherapy being used often influences the second or third AED added to combination therapy regimens. Selecting AED combinations that have potentially complementary mechanisms of action is reasonable based on the limited data available. If the patient is established on treatment with an enzyme-inducing AED (e.g. carbamazepine, phenytoin, or phenobarbital), it may be desirable to add AEDs that carry a modest or low risk of clinically relevant pharmacokinetic interactions (e.g. lacosamide, levetiracetam, topiramate, pregabalin, or zonisamide). 39 If a patient does not reach a seizure-free state on a two-drug regimen but suffers notably fewer and/or less severe seizures, a third AED with different pharmacologic properties can be added in small doses, concurrently reducing the dose of one or both of the initial AEDs to avoid drug overload. 40 Third-line agents including tiagabine, clobazam, and acetazolamide may be added. Vigabatrin and felbamate remain drugs of last resort because of their propensity to produce visual field defects 60 and aplastic anemia and hepatotoxicity, 61 respectively. However, treatment with four or more drugs is unlikely to be successful. To summarize, not all patients are suited to one treatment strategy. It has been argued that strategies should be tailored to each patient's requirements depending on patient scenario, and this logic resonates. 38 If a first AED fails due to lack of efficacy but produces no side effects its dose should be increased within prescribing limits. The limit is arbitrary to an extent and it is possible to reach a point beyond which increasing the dose will not be beneficial despite the absence of side effects. Conversely, if a drug fails due to a lack of efficacy and side effects, it is possible to revert back to a lower dose that is better tolerated and to add a second AED. Table 1 summarizes other scenarios for which add-on or substitution therapies may be beneficial. In conclusion, polytherapy is a rational and effective maneuver for many patients. Furthermore, polytherapy will be established on a much firmer foundation by studies comparing various combinations in a rigorous manner for specific seizure types and patients. As for all situations in a medical setting, following a blind strategy without consideration of individual circumstances is never in the best interest of the patient.
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The Future of Antiepileptic Drugs and Emerging Novel Therapies
Failure of the newer AEDs to produce significant improvements in seizure control for the majority of patients refractory to older AEDs continues to provide impetus for the development of more effective treatments. 66 The limited success with newer AEDs might be attributed to the strategies by which they were developed, which mainly relied on random screening in relatively crude animal seizure models, structural alteration of existing agents, or rational drug design based on a limited understanding of the pathophysiology of seizures. 67 Conversely, the surprising ability of these albeit unsophisticated approaches to identify compounds with unique pharmacologic profiles has been highlighted, including novel mechanisms of action, broader efficacy spectra, or improved pharmacokinetics. 68 It is likely that future improvements in outcome will be incremental rather than transformative. 68 Regardless, there is a more focused approach with the development of compounds boasting novel mechanisms of actions that act on molecular targets derived from advances in the knowledge of seizure pathogenesis. 69 Time will tell whether these pharmacologic improvements will translate into superior effectiveness over the existing agents in clinical practice.
Notably, many of these emerging compounds are concurrently being developed for the treatment of other neurological or psychiatric conditions, some of which may co-exist with epilepsy. These wider choices will provide a welcome expansion of the pharmacological armamentarium for the treatment of drug-resistant epilepsy and will potentially allow drug selection to be more individualized. 70 However, drugs developed under current strategies and administered systematically are unlikely to provide the answer to the challenges of drug-resistant epilepsy. They are failing because of limited approaches to drug development and intrinsic patient factors, including possible genetic differences and impaired access of AEDs to the seizure focus, 66 that have not been addressed adequately. To overcome these problems, novel drug-delivery techniques (e.g. polymers) aiming to bypass the systematic circulation to allow drugs to reach the epileptogenic focus directly are being investigated. 71 Furthermore, animal models of chronic epilepsy instead of acute seizures should be better used for pre-clinical screening of compounds. 70 It is critical to decipher the pathogenesis of pharmacoresistance. One method to achieve this is to study ways to identify patients who would or would not respond to particular AEDs with known mechanisms of action. Pharmacogenomics holds the potential to inform prescription of existing drugs or develop novel compounds based on the individual genetic profiles of patients, but conceptual and technical hurdles remain to be overcome before its clinical impact can be anticipated.
However, the ultimate challenge in epilepsy therapeutics is to identify pharmacologic approaches that will prevent the development and French and Faught, 2009. 19 
U S N E U R O L O G Y
Conclusions
It will not be possible to determine which polytherapy regimens are most effective with the least toxicity for different seizure types unless more information becomes available. It is known that certain types of polytherapy are effective and well-tolerated in certain patients, but physicians need guidance on which specific regimens to select, particularly which add-on AED would be best to combine with specific monotherapy drugs. Although this can already be predicted to some extent based on adverse event profiles, it cannot be predicted satisfactorily based upon efficacy. The solution to this dilemma is to conduct well-controlled studies of specific combinations. As it is not possible to test all the different pairs of drugs and our knowledge of drug mechanisms is fragmentary, shrewd selection of AEDs for polytherapy studies should be based on what 'ought' to be a rational combination (based on presumed major mechanism of action) and more based on the empiric results from animal studies. Experiments, whether human or animal, must take into account pharmacokinetic interactions and must measure toxicity, not just efficacy. 19 n
